Showing results (1-10 of 35) with videos related to
Sort By:
Pageof 4
American Journal of Clinical and Experimental Immunology|July 26, 2013
Epigenetic regulation of the TRAIL/Apo2L apoptotic pathway by histone deacetylase inhibitors: an attractive approach to bypass melanoma immunotherapy resistanceAli R Jazirehi, Dylan ArleAmerican Journal of Cancer Research|April 10, 2012
Therapeutic implications of targeting the PI3Kinase/AKT/mTOR signaling module in melanoma therapyAli R Jazirehi, Peter B Wenn, Mohsen DamavandInternational Journal of Molecular Sciences|November 13, 2021
Molecular Analysis of Elements of Melanoma Insensitivity to TCR-Engineered Adoptive Cell TherapyAli R JazirehiAnti-Cancer Drugs|August 4, 2010
Regulation of apoptosis-associated genes by histone deacetylase inhibitors: implications in cancer therapyAli R JazirehiOncogene|March 25, 2005
Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic interventionAli R Jazirehi, Benjamin BonavidaMolecular Cancer Therapeutics|January 30, 2004
Resveratrol modifies the expression of apoptotic regulatory proteins and sensitizes non-Hodgkin's lymphoma and multiple myeloma cell lines to paclitaxel-induced apoptosisAli R Jazirehi, Benjamin BonavidaMethods in Molecular Biology (Clifton, N.J.)|April 26, 2011
Development of rituximab-resistant B-NHL clones: an in vitro model for studying tumor resistance to monoclonal antibody-mediated immunotherapyAli R Jazirehi, Benjamin BonavidaMolecular Cancer Therapeutics|April 26, 2012
Proteasome inhibition blocks NF-κB and ERK1/2 pathways, restores antigen expression, and sensitizes resistant human melanoma to TCR-engineered CTLsAli R Jazirehi, James S EconomouAmerican Journal of Cancer Research|May 18, 2016
CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's LymphomasAlexandra S Onea, Ali R JazirehiCancers|June 16, 2018
Overcoming Resistance of Human Non-Hodgkin's Lymphoma to CD19-CAR CTL Therapy by Celecoxib and Histone Deacetylase InhibitorsAntoni Xavier Torres-Collado, Ali R JazirehiPageof 4